Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects

NCT00388180 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00388180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00388180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
December 31, 2004
Completion date
Not reported
Enrollment
71 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidaemias, hypercholesterolemia, obesity